Keyphrases
Apolipoprotein A-I (ApoA-I)
100%
Atherosclerotic Cardiovascular Disease (ASCVD)
33%
Atherosclerotic Disease
33%
Atherosclerotic Lesions
66%
Atherosclerotic Plaque
66%
Atherosclerotic Plaque Regression
33%
Cholesterol Efflux
33%
Clinically Significant
33%
Collaborative Laboratory
33%
Effective Therapy
33%
HMG-CoA Reductase Inhibitors
33%
LDL Receptor Knockout Mice
33%
Leading Causes of Death
33%
Nanofibers
66%
Novel Paradigm
33%
Novel Therapies
33%
Peptide Amphiphile Nanofibers
33%
Plaque
33%
Plaque Growth
33%
Plaque Regression
33%
Regress
100%
Self-assembling Peptide
33%
Statin Drugs
33%
Statins
33%
Successful Completion
33%
Targeted Nanotherapeutics
100%
Targeting Effect
33%
Therapeutic Effect
33%
United States
33%
Pharmacology, Toxicology and Pharmaceutical Science
Amphiphile
33%
Atherosclerosis
100%
Combination Therapy
33%
Coronary Artery Atherosclerosis
33%
Diseases
33%
Effusion
33%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
66%
Low Density Lipoprotein Receptor Knockout Mouse
33%
Nanofiber
100%
Statin (Protein)
33%
Therapeutic Effect
33%
Medicine and Dentistry
Amphophile
33%
Atherosclerosis
100%
Combination Therapy
33%
Diseases
33%
Effusion
33%
LDL Receptor
33%
Nanofiber
100%
Statin
100%
Therapy Effect
33%